An Observational Study to Learn More About How Acceptable and Practical a Digital Remote Monitoring Tool (Luscii) is in People With Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Sponsor: Bayer
Trial Details
| Condition | Transthyretin Amyloid Cardiomyopathy (ATTR-CM) |
| Intervention | Luscii |
| Status | Not_yet_recruiting |
| Participants | 60 |
| Est. Completion | 22 Nov 2027 |
| Last Updated | 11 June 2026 |
Primary Outcome
Acceptance of Luscii among medical professionals; Acceptance of Luscii among participants with ATTR-CM; Feasibility of Luscii for medical professionals; Feasibility of Luscii for participants with ATTR-CM; Self-reported acceptance and feasibility of the ATTR-CM-specific Luscii configuration among participants; Self-reported acceptance and feasibility of the ATTR-CM-specific Luscii configuration among medical professionals
Eligibility Criteria
Inclusion Criteria
Inclusion Criteria: * Adult (≥18 years at the date of signing the informed consent form (ICF)). * Diagnosis of either wild-type or variant ATTR-CM. * Treatment with a drug approved for ATTR-CM, including newly prescribed therapy at the initial visit. * Signed ICF. * Access to and basic ability to use a personal smartphone with internet connectivity sufficient to install and operate the Luscii contact application. Exclusion Criteria: * Participation in an investigational program with interventions outside of routine clinical practice. * Patients who are unable to provide consent, including those whose consent would need to be given by a legal representative.
Trial Sites
🇦🇺 Australian Sites (1)
Countries
This content is for educational purposes for healthcare professionals only and does not constitute clinical advice. Clinical decisions should be based on individual patient assessment, current guidelines, and appropriate specialist consultation. Editorial Standards · Privacy Policy · Terms of Service